TABLE 2.

Summary of treatment-related AEs (NCI CTCAE grades) occurring >10% in patients of all groups.

Dose levels	50 mg (N = 3)			100 mg (N = 3)			150 mg (N = 3)			220 mg (N = 3)			300 mg (N = 6)			350 mg (N = 4)			400 mg (N = 3)
AEs, n	Grade1	Grade2	Grade3	Grade1	Grade2	Grade3	Grade1	Grade2	Grade3	Grade1	Grade2	Grade3	Grade1	Grade2	Grade3	Grade1	Grade2	Grade3	Grade1	Grade2	Grade3
Acne-like rash	0	0	0	0	0	0	2	0	0	2	1	0	6	0	0	1	2	0	3	0	0
Paronychia	0	0	0	0	0	0	0	2	0	1	2	0	2	0	0	2	1	0	1	1	0
Diarrhea	1	0	0	0	0	0	0	0	0	0	0	0	3	2	0	1	1	1	3	0	0
Anemia	0	1	0	1	1	0	2	0	0	1	0	0	2	2	0	1	0	0	1	0	0
Hand-foot skin reaction	0	0	0	0	0	0	0	1	0	0	3	0	2	0	0	2	1	0	1	1	0
Stomatitis	0	0	0	0	0	0	1	0	0	2	0	0	0	4	0	1	1	0	1	1	0
Decreased lymphocyte	0	1	0	0	0	2	1	1	0	0	1	0	0	1	1	0	0	0	0	2	0
Nausea	0	0	0	0	0	0	1	0	0	0	0	1	3	1	0	1	0	0	2	0	0
Hypoalbuminemia	1	0	0	0	0	0	1	0	0	0	1	0	3	1	0	1	0	0	0	0	0
Weight loss	0	0	0	0	0	0	0	0	0	2	0	0	1	2	0	2	0	0	0	1	0
Hematuria	1	0	0	0	0	0	0	0	0	1	0	0	1	1	0	1	0	0	1	0	0
Hyperglycemia	0	0	0	0	0	0	1	0	0	1	0	0	2	0	0	0	0	0	0	1	0
Emesis	0	0	0	0	0	0	1	0	0	0	0	0	2	0	0	0	0	0	1	1	0
Elevated alanine aminotransferase	0	0	0	0	0	0	1	0	0	0	0	0	2	1	0	0	0	0	0	0	0
Decreased total protein	0	0	0	0	0	0	0	0	0	1	0	0	1	1	0	1	0	0	0	0	0
Proteinuria	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	1	0	0	0	0	0
Xerostomia	0	0	0	0	0	0	0	0	0	0	0	0	3	0	0	0	0	0	0	0	0
Elevated aspartate aminotransferase	0	0	0	0	0	0	1	0	0	0	0	0	2	0	0	0	0	0	0	0	0

NOTE: No treatment-related Grade 4–5 AEs were observed in all dose cohorts during the study.

AE, adverse event; NCI CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events.